Categories
News

A Message to the UK Government and the BBC – Professor Sucharit Bhakdi, Oracle Films

Professor Sucharit Bhakdi: “You are now witnessing the greatest crime that England has ever committed in its history.”

Categories
News

Israel is now the world’s Covid hotspot: Cases soar despite country’s trail-blazing vaccine roll-out – sparking fears other highly-vaccinated countries will be hit by another wave due to jabs’ waning immunity – Daily Mail

Israel has become the Covid capital of the world just months after leading the charge on vaccines, according to data that shows jab protection is waning. Stats compiled by an Oxford University-based research platform show Israel recorded 1,892 cases per million people on Wednesday — nearly 0.2 per cent of the entire population in a single day. That was significantly higher than second worst-hit Mongolia where the rate was 1,119 per million and double the figures for Kosovo (980), Georgia (976) and Montenegro (909), which rounded out the top five

http://archive.today/2021.09.02-232457/https://www.dailymail.co.uk/news/article-9951117/Israel-worlds-Covid-hotspot-0-2-population-catching-yesterday.html

Categories
News

Covid infection protection waning in double jabbed – BBC

The real-world study includes data on positive Covid PCR test results between May and July 2021 among more than a million people who had received two doses of Pfizer or AstraZeneca vaccine.

Protection after two shots of Pfizer decreased from 88% at one month to 74% at five to six months.

For AstraZeneca, the fall was from 77% to 67% at four to five months.

http://archive.today/2021.08.25-105339/https://www.bbc.com/news/health-58322882

Categories
Publications

Does the FDA think these data justify the first full approval of a covid-19 vaccine? – BMJ

I reiterate our call: “slow down and get the science right—there is no legitimate reason to hurry to grant a license to a coronavirus vaccine.”

FDA should be demanding that the companies complete the two year follow-up, as originally planned (even without a placebo group, much can still be learned about safety). They should demand adequate, controlled studies using patient outcomes in the now substantial population of people who have recovered from covid. And regulators should bolster public trust by helping ensure that everyone can access the underlying data.

http://archive.today/2021.08.24-174356/https://blogs.bmj.com/bmj/2021/08/23/does-the-fda-think-these-data-justify-the-first-full-approval-of-a-covid-19-vaccine/

Categories
Publications

Human IgG and IgA responses to COVID-19 mRNA vaccines – PLOS ONE

SARS-CoV-2 spike antigen-specific IgG and IgA elicited by infection mediate viral neutralization and are likely an important component of natural immunity, however, limited information exists on vaccine induced responses. We measured COVID-19 mRNA vaccine induced IgG and IgA in serum serially, up to 145 days post vaccination in 4 subjects. Spike antigen-specific IgG levels rose exponentially and plateaued 21 days after the initial vaccine dose. After the second vaccine dose IgG levels increased further, reaching a maximum approximately 7–10 days later, and remained elevated (average of 58% peak levels) during the additional >100 day follow up period. COVID-19 mRNA vaccination elicited spike antigen-specific IgA with similar kinetics of induction and time to peak levels, but more rapid decline in serum levels following both the 1st and 2nd vaccine doses (<18% peak levels within 100 days of the 2nd shot). The data demonstrate COVID-19 mRNA vaccines effectively induce spike antigen specific IgG and IgA and highlight marked differences in their persistence in serum.

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0249499

Categories
Videos

Dr David Bauer: ‘Pfizer vaccine produces fewer key antibodies’ – MSN News

Dr Bauer of the Francis Crick Institute explains that the Pfizer vaccine produces 5-6 times fewer neutralising antibodies that play a key role in protecting us from the Indian variant. He suggests that booster Pfizer jabs will be essential.

https://www.msn.com/en-gb/news/other/dr-david-bauer-pfizer-vaccine-produces-fewer-key-antibodies/vi-AAKHPO1

Categories
Publications

Pfizer-BioNTech vaccine recipients have lower antibody levels targeting the Delta variant first discovered in India – The Francis Crick Institute

Levels of antibodies in the blood of vaccinated people that are able to recognise and fight the new SARS-CoV-2 Delta variant first discovered in India (B.1.617.2) are on average lower than those against previously circulating variants in the UK, according to new laboratory data from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre, published today (Thursday) as a Research letter in The Lancet.

The results also show that levels of these antibodies are lower with increasing age and that levels decline over time, providing additional evidence in support of plans to deliver a vaccination boost to vulnerable people in the Autumn. 

https://www.crick.ac.uk/news/2021-06-03_pfizer-biontech-vaccine-recipients-have-lower-antibody-levels-targeting-the-delta-variant-first-discovered-in-india

Categories
Publications

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination – The Lancet

In the case of single-dose recipients, our data show that NAbTs are significantly lower against B.1.617.2 and B.1.351 VOCs relative to B.1.1.7, implying that although a single dose might still afford considerably more protection than no vaccination, single-dose recipients are likely to be less protected against these SARS-CoV-2 variants. These data therefore suggest that the benefits of delaying the second dose, in terms of wider population coverage and increased individual NAbTs after the second dose,7 must now be weighed against decreased efficacy in the short-term, in the context of the spread of B.1.617.2. Worldwide, our data highlight the ongoing need to increase vaccine supply to allow all countries to extend second-dose protection as quickly as possible.

In the longer term, we note that both increased age and time since the second dose of BNT162b2 significantly correlate with decreased NAb activity against B.1.617.2 and B.1.351—both of which are also characteristic of the population in the UK at highest risk of severe COVID-19 (ie, older and vaccinated earlier), independent of other existing factors such as compromised immune status or comorbidity, or geographic-specific responses to vaccination.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01290-3/fulltext